We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Read MoreHide Full Article
Solid Biosciences Inc. (SLDB - Free Report) announced that the FDA has cleared its investigational new drug (IND) application to begin clinical studies on its novel AAV-based gene therapy candidate, SGT-212, for the treatment of Friedreich’s ataxia (FA).
Per the company, SGT-212 is the only full-length frataxin replacement gene therapy candidate that targets the cardiac manifestations of FA.
SGT-212 is being developed to treat the neurologic and systemic clinical manifestations of FA to address the full spectrum of disease progression.
Shares of the company were up 17.4% in after-hours trading on Jan. 7 following the announcement of the news. The stock was also up in pre-market trading on Jan. 8.
In the past year, shares of Solid Biosciences have plunged 51.4% compared with the industry’s decline of 15.7%.
Image Source: Zacks Investment Research
More on SLDB's FA Gene Therapy Candidate
The above IND was backed by robust preclinical data on SGT-212.
SLDB plans to initiate a phase Ib study SGT-212 for treating FA in the second half of 2025.
The first-in-human, open-label, dose-finding study will evaluate the safety and tolerability of systemic intravenous infusion and direct intradentate nuclei (IDN) infusion of SGT-212 in non-ambulatory and ambulatory adult patients with FA.
Per management, the dual route of administration helps in the direct delivery of SGT-212 to the heart and cerebellum to potentially treat the most significant symptoms of FA.
The gene therapy candidate provides a differentiated approach to treat the underlying disease.
Other Players in the FA Market
We note that FA is a rare disease. Hence, a few companies have developed or are developing a treatment for the disease.
Drug giant, Biogen (BIIB - Free Report) currently markets Skyclarys, which is the first approved treatment for FA. The FDA approved the drug in 2023, while it was approved in Europe in February 2024.
The acquisition of Reata Pharmaceuticals in September 2023 added this rare disease drug to Biogen’s portfolio.
Per BIIB, the launch of Skyclarys is progressing well in the United States and the European Union as the drug is witnessing increased demand globally.
Clinical-stage company Larimar Therapeutics (LRMR - Free Report) is developing its lead pipeline candidate nomlabofusp (CTI-1601) as a potential treatment for FA.
Larimar Therapeutics plans to file a biologics license application seeking approval of nomlabofusp for treating FA in the second half of 2025.
LRMR believes that nomlabofusp has the potential to be the first frataxin protein replacement therapy for patients with FA.
SLDB's Zacks Rank & Stock to Consider
Solid Biosciences currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares of PBYI have declined 21.7%.
PBYI’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.78%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Solid Biosciences Inc. (SLDB - Free Report) announced that the FDA has cleared its investigational new drug (IND) application to begin clinical studies on its novel AAV-based gene therapy candidate, SGT-212, for the treatment of Friedreich’s ataxia (FA).
Per the company, SGT-212 is the only full-length frataxin replacement gene therapy candidate that targets the cardiac manifestations of FA.
SGT-212 is being developed to treat the neurologic and systemic clinical manifestations of FA to address the full spectrum of disease progression.
Shares of the company were up 17.4% in after-hours trading on Jan. 7 following the announcement of the news. The stock was also up in pre-market trading on Jan. 8.
In the past year, shares of Solid Biosciences have plunged 51.4% compared with the industry’s decline of 15.7%.
Image Source: Zacks Investment Research
More on SLDB's FA Gene Therapy Candidate
The above IND was backed by robust preclinical data on SGT-212.
SLDB plans to initiate a phase Ib study SGT-212 for treating FA in the second half of 2025.
The first-in-human, open-label, dose-finding study will evaluate the safety and tolerability of systemic intravenous infusion and direct intradentate nuclei (IDN) infusion of SGT-212 in non-ambulatory and ambulatory adult patients with FA.
Per management, the dual route of administration helps in the direct delivery of SGT-212 to the heart and cerebellum to potentially treat the most significant symptoms of FA.
The gene therapy candidate provides a differentiated approach to treat the underlying disease.
Other Players in the FA Market
We note that FA is a rare disease. Hence, a few companies have developed or are developing a treatment for the disease.
Drug giant, Biogen (BIIB - Free Report) currently markets Skyclarys, which is the first approved treatment for FA. The FDA approved the drug in 2023, while it was approved in Europe in February 2024.
The acquisition of Reata Pharmaceuticals in September 2023 added this rare disease drug to Biogen’s portfolio.
Per BIIB, the launch of Skyclarys is progressing well in the United States and the European Union as the drug is witnessing increased demand globally.
Clinical-stage company Larimar Therapeutics (LRMR - Free Report) is developing its lead pipeline candidate nomlabofusp (CTI-1601) as a potential treatment for FA.
Larimar Therapeutics plans to file a biologics license application seeking approval of nomlabofusp for treating FA in the second half of 2025.
LRMR believes that nomlabofusp has the potential to be the first frataxin protein replacement therapy for patients with FA.
SLDB's Zacks Rank & Stock to Consider
Solid Biosciences currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Puma Biotechnology, Inc. (PBYI - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares of PBYI have declined 21.7%.
PBYI’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.78%.